BioNTech SE - American Depositary Shares (NQ:BNTX)

97.37 -0.93 (-0.95%)

Delayed Quote Updated: 1:16 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

May 22, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

May 15, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM ↗

May 15, 2026

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a...

Via MarketBeat

BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides ↗

May 05, 2026

Via Chartmill

BioNTech SE (NASDAQ:BNTX) Stock Plummets 17% on Q4 Loss and Co-Founders' Planned Exit ↗

March 10, 2026

Via Chartmill

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗

May 13, 2026

Investors can find much better opportunities.

Via The Motley Fool

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗

May 11, 2026

This may be an excellent deal for those focused on the long game.

Via The Motley Fool

Topics Intellectual Property

BioNTech Announces New ADS Repurchase Program

May 07, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

May 05, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

April 21, 2026

From BioNTech SE

Via GlobeNewswire

2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗

April 15, 2026

Recent performances don't tell the whole story.

Via The Motley Fool

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

April 11, 2026

From BioNTech SE

Via GlobeNewswire

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the...

Via Finterra

Topics Initial Public Offering

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

March 24, 2026

From BioNTech SE

Via GlobeNewswire

The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery

March 16, 2026

The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper...

Via MarketMinute

Topics Artificial Intelligence Initial Public Offering Stocks

Why BioNTech Stock Is Getting Crushed Today ↗

March 10, 2026

Nothing about the recent past, present, or foreseeable future seems all that compelling.

Via The Motley Fool

Gapping stocks in Tuesday's session ↗

March 10, 2026

Via Chartmill

BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier

March 10, 2026

In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the...

Via MarketMinute

Stay updated with the stocks that are on the move in today's pre-market session. ↗

March 10, 2026

Via Chartmill

Why Did BNTX Stock Tumble 17% Pre-Market Today? ↗

March 10, 2026

BioNTech co-founders Ugur Sahin and Özlem Türeci are set to leave the company to head the new venture.

Via Stocktwits

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

March 10, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

March 10, 2026

From BioNTech SE

Via GlobeNewswire

The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology

March 06, 2026

On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a...

Via Finterra

Topics Initial Public Offering Intellectual Property

Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement

March 05, 2026

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant...

Via MarketMinute

Topics Intellectual Property Lawsuit

Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era

March 05, 2026

Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level...

Via Finterra

Topics Intellectual Property

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

February 24, 2026

From BioNTech SE

Via GlobeNewswire

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...

Via Finterra

Topics Economy Intellectual Property

Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology

February 11, 2026

Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical...

Via Finterra

Topics Artificial Intelligence Initial Public Offering Intellectual Property

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

January 28, 2026

From BioNTech SE

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.